Remdesivir and its antiviral activity against COVID-19: A systematic review
Andri Frediansyaha b✉, Firzan Nainuc✉, Kuldeep Dhamad✉, Mudatsir Mudatsire f g✉, Harapan Harapane f g✉
- aDepartment of Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, Tübingen, 72076, Germany
- bResearch Division for Natural Product Technology (BPTBA), Indonesian Institute of Sciences (LIPI), Wonosari, 55861, Indonesia
- cFaculty of Pharmacy, Hasanuddin University, Tamalanrea, Makassar, 90245, Indonesia
- dDivision of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India
- eDepartment of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia
- fMedical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia
- gTropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh, 23111, Indonesia
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
BACKGROUND: The aim of this study was to summarize the antiviral activities of remdesivir against SARS-CoV-2, the causative agent of COVID-19. METHODS: Available publications were systematically explored on some databases and gray literature was examined. Publications were discussed narratively. RESULTS: Remdesivir inhibits SARS-CoV-2 replication, reduces viral load, and exerts protective effects in SARS-CoV-2 infected animals. Remdesivir also reduces the pathological process, alleviates mild symptoms, and improves pulmonary lesions in SARS-CoV-2-infecetd animals. Remdesivir has been used as a compassionate drug for treating COVID-19 patients. CONCLUSION: Although remdesivir has shown potent antiviral activities, more efficacy assessments are urgently warranted in clinical trials.
TL;DRAlthough remdesivir has shown potent antiviral activities, more efficacy assessments are urgently warranted in clinical trials. (Semantic Scholar)